These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 20846529)

  • 1. An update to "The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe".
    Jit M; Mangen MJ; Melliez H; Yazdanpanah Y; Bilcke J; Salo H; Edmunds WJ; Beutels P
    Vaccine; 2010 Nov; 28(47):7457-9. PubMed ID: 20846529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe.
    Jit M; Bilcke J; Mangen MJ; Salo H; Melliez H; Edmunds WJ; Yazdan Y; Beutels P
    Vaccine; 2009 Oct; 27(44):6121-8. PubMed ID: 19715781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales.
    Atkins KE; Shim E; Carroll S; Quilici S; Galvani AP
    Vaccine; 2012 Nov; 30(48):6766-76. PubMed ID: 23000223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An economic analysis of rotavirus vaccination in Italy.
    Giammanco MD; Coniglio MA; Pignato S; Giammanco G
    Vaccine; 2009 Jun; 27(29):3904-11. PubMed ID: 19446934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating rotavirus vaccination in England and Wales. Part I. Estimating the burden of disease.
    Harris JP; Jit M; Cooper D; Edmunds WJ
    Vaccine; 2007 May; 25(20):3962-70. PubMed ID: 17395343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comment on: the cost effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe.
    Campbell DI
    Vaccine; 2011 May; 29(21):3731; author reply 3732-3. PubMed ID: 21184859
    [No Abstract]   [Full Text] [Related]  

  • 7. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries.
    Rheingans RD; Antil L; Dreibelbis R; Podewils LJ; Bresee JS; Parashar UD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S16-27. PubMed ID: 19817595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination.
    Jit M; Edmunds WJ
    Vaccine; 2007 May; 25(20):3971-9. PubMed ID: 17400341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rotavirus vaccination in Europe: drivers and barriers.
    Parez N; Giaquinto C; Du Roure C; Martinon-Torres F; Spoulou V; Van Damme P; Vesikari T
    Lancet Infect Dis; 2014 May; 14(5):416-25. PubMed ID: 24758998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of potential medical and economic benefits of universal rotavirus vaccination in Greece.
    Syriopoulou V; Kafetzis D; Theodoridou M; Syrogiannopoulos GA; Mantagos S; Trimis G; Mavrikou M; Konstantopoulos A
    Acta Paediatr; 2011 May; 100(5):732-9. PubMed ID: 21223372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.
    Tilson L; Jit M; Schmitz S; Walsh C; Garvey P; McKeown P; Barry M
    Vaccine; 2011 Oct; 29(43):7463-73. PubMed ID: 21821085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care'' disease impact in Belgium.
    Bilcke J; Van Damme P; Beutels P
    Med Decis Making; 2009; 29(1):33-50. PubMed ID: 18948433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of childhood rotavirus vaccination in Germany.
    Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O
    Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation.
    Fisman DN; Chan CH; Lowcock E; Naus M; Lee V
    Vaccine; 2012 Dec; 30(52):7601-7. PubMed ID: 23107595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan.
    Itzler RF; Chen PY; Lac C; El Khoury AC; Cook JR
    J Med Econ; 2011; 14(6):748-58. PubMed ID: 21919673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the introduction of universal rotavirus vaccination in the Netherlands.
    Zomer TP; van Duynhoven YT; Mangen MJ; van der Maas NA; Vennema H; Boot H; de Melker HE
    Vaccine; 2008 Jul; 26(29-30):3757-64. PubMed ID: 18514975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of rotavirus vaccination programs in Taiwan.
    Chang WC; Yen C; Chi CL; Wu FT; Huang YC; Lin JS; Huang FC; Tate JE; Wu HS; Hsiung CA
    Vaccine; 2013 Nov; 31(46):5458-65. PubMed ID: 24060569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
    Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
    Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia.
    De la Hoz F; Alvis N; Narváez J; Cediel N; Gamboa O; Velandia M
    Vaccine; 2010 May; 28(22):3856-64. PubMed ID: 20347057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Projected cost-effectiveness of rotavirus vaccination for children in Asia.
    Podewils LJ; Antil L; Hummelman E; Bresee J; Parashar UD; Rheingans R
    J Infect Dis; 2005 Sep; 192 Suppl 1():S133-45. PubMed ID: 16088797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.